Mereo BioPharma Group
MREO | NASDAQ
$0.49
-$0.04 (-7.04%)
At close: Jan 26, 2026, 3:55 PM ET
Market Data
Market Cap $84.16M
Enterprise Value N/A
Beta 0.36
Average Volume N/A
Shares Outstanding (Diluted) 159.99M
Shares Change YoY N/A
Institutional Ownership N/A
Exchange NASDAQ
ISIN N/A
Valuation
PE Ratio -2.03
Forward PE N/A
PEG Ratio -0.14
Forward PEG N/A
PS Ratio 168.32
Forward PS N/A
PB Ratio 1.81
P/FCF Ratio N/A
P/Adj. FCF Ratio N/A
P/OCF Ratio N/A
EV/Sales 71.72
EV/EBIT N/A
EV/EBITDA -0.83
EV/FCF N/A
Earnings Yield N/A
FCF Yield -46.2%
Adj. FCF Yield N/A
Financial Health
Net Cash $48.3M
Total Debt N/A
Cash & Short-Term Investments N/A
Total Assets N/A
Current Ratio 8.71
Quick Ratio N/A
Debt / Equity Ratio N/A
Debt / EBITDA N/A
Debt / FCF N/A
OCF / Debt N/A
Interest Coverage -77.20
Altman Z-Score N/A
Piotroski F-Score 2
Margins & Profitability
Gross Profit Margin 19.1%
Operating Profit Margin -9369.9%
EBITDA Margin N/A
Net Profit Margin -8301.5%
FCF Margin -7777.4%
Adj. FCF Margin N/A
SBC / Revenue N/A
SBC Impact (per share) -17.7%
Returns
Return on Assets -77.4%
Return on Equity -74.8%
Return on Invested Capital -96.3%
Return on Capital Employed N/A
Return on Tangible Assets N/A
Historical Growth (CAGR)
Revenue CAGR 3Y -33.3%
Revenue CAGR 5Y N/A
Revenue CAGR 10Y N/A
EPS CAGR 3Y -33.4%
EPS CAGR 5Y 20.0%
EPS CAGR 10Y N/A
FCF CAGR 3Y -110.1%
FCF CAGR 5Y 8.9%
FCF CAGR 10Y N/A
Analyst Forecasts
Analyst Rating Buy
Analyst Count N/A
EPS Growth Next 3Y N/A
Revenue Growth Next 3Y N/A
Earnings Date N/A
EPS Estimate (next Q) N/A
EPS Growth Est (next Q) N/A
Revenue Est (next Q) N/A
Revenue Growth Est (next Q) N/A
Fair Value Estimates
Graham Number N/A
Graham Upside N/A
Lynch Fair Value N/A
Lynch Upside N/A
Price Target $0.83
Price Target Upside N/A
Income Statement
Revenue $500K
Gross Profit N/A
Operating Income N/A
EBITDA N/A
Net Income $-41.51M
EPS (Diluted) -$0.27
Revenue / Employee $13.89K
Profit / Employee $-1.15M
Employees N/A
Add to Watchlist
Select watchlists to add or remove MREO